Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
Status:
Completed
Trial end date:
2019-08-31
Target enrollment:
Participant gender:
Summary
This is a study of TRC105 in combination with standard dose pazopanib compared to single
agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g.,
metastatic or bulky disease, and disease for which surgical resection would carry an
unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.